

# **Emricasan, pan-Caspase inhibitor**

Catalog	Unit
TBI4280-5MG	5 mg
TBI4280-25MG	25 mg

#### **Product Details**

Formal Name: (3S)-3-[[(2S)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-

tetrafluorophenoxy)pentanoic acid

Alternate Names: IDN-6556; PF-03491390

 $\label{eq:molecular Formula: C26H27F4N3O7} \textbf{Molecular Formula: } C_{26}H_{27}F_4N_3O_7$ 


**Formula Weight:** 569.51 **CAS Number:** 254750-02-2

**Purity:** >98%

Formulation: powder

**Solubility:** Soluble in DMSO (up to at least 20 mg/ml)

Storage:  $-20^{\circ}$ C Stability:  $\geq 2$  years.



## **Applications**

pan-Caspase inhibitor

## **Functions**

Liver-targeted antiapoptotic pan-caspase inhibitor. It has been investigated as a hepatoprotective agent in the treatment of liver ischemia and NASH/NAFLD liver injury. Emricasan protected SNB-19 cells against cell death induced by Zika virus strains MR766, FSS13025, and PRVABC59. Emricasan improves the viability of hPSCs and their differentiated progeny when used in a small molecule cocktail (CEPT) containing chroman 1, polyamines and trans-ISRIB.

### **Application Procedures**

First dissolved in DMSO (up to at least 20 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 1 month.

For research use only.